Data-driven medicine company SOPHiA GENETICS has completed the acquisition of French tech company Interactive Biosoftware (IBS).

IBS created Alamut, which is said to be the most used decision support software for clinical genomic data interpretation.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Currently deployed in more than 450 hospitals, the software is complementary to SOPHiA GENETICS’ offering.

“With the latest acquisition, SOPHiA GENETICS will be able to reinforce its proposal to continuously support hospitals and patients with powerful technologies.”

The acquisition is aimed at further accelerating the adoption of data-driven medicine across the globe.

Interactive Biosoftware CEO and founder André Blavier said: “Interactive Biosoftware has been highly successful in providing powerful technology for experts with complex genomic interpretation needs.

“It is great to join SOPHiA GENETICS unique approach and position to accelerate Data-Driven Medicine’s adoption.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the latest acquisition, SOPHiA GENETICS will be able to reinforce its proposal to continuously support hospitals and patients with powerful technologies.

Following the deal, Interactive Biosoftware’s expertise and teams are set to join SOPHiA GENETICS’ workforce.

SOPHiA GENETICS CEO and co-founder Jurgi Camblong said: “We are very excited about the acquisition of Interactive Biosoftware. Both SOPHiA AI and Alamut are technologies trusted by the healthcare community and focus on patient-centric innovation.

“The addition of Alamut marks a big step in our aim to help clinicians better diagnose patients equally. With a community of now over 900 teaching hospitals using our technologies we are in a unique position to connect clinicians and enable them to share knowledge.”

SOPHiA GENETICS has developed SOPHiA AI, the most advanced technology for clinical genomics, helping healthcare professionals better diagnose and treat patients.